NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas

This is a randomized, double-blind, vehicle-controlled, parallel group dose response study evaluating the safety and effectiveness of 2 concentrations of NFX-179 Gel in subjects with cutaneous neurofibromas. At Visit 1, the investigator will identify 10 Target cNFs that fulfil the enrollment criteria. The Target cNFs must be located on the subject's face, anterior trunk, or upper extremities. Two Target cNFs must be on the face and 8 must be on the anterior trunk or upper extremities. The study medication will be applied topically QD to the Target cNFs for 182days (26 weeks). During the duration of the study subjects will be evaluated for safety and efficacy.

Study Overview

• Status: Completed
• Conditions: Neurofibromatosis 1; Cutaneous Neurofibroma
• Intervention / Treatment: Drug: NFX-179 gel; Drug: Vehicle gel

• Study Type: Interventional
• Enrollment (Actual): 199
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72205-7199
      • University of Arkansas for Medical Sciences
    • Rogers, Arkansas, United States, 72758
      • Northwest Arkansas Clinical Trials Center, PLLC
  • California
    • Fremont, California, United States, 94538
      • Center for Dermatology Clinical Research, Inc.
    • Los Angeles, California, United States, 90027
      • Children's Hospital Los Angeles
    • San Diego, California, United States, 92123
      • University Clinical Trials, Inc.
  • District of Columbia
    • Washington, District of Columbia, United States, 20010
      • Children's National Hospital
  • Florida
    • Gainesville, Florida, United States, 32610
      • University of Florida
  • Illinois
    • Evanston, Illinois, United States, 60077
      • NorthShore University HealthSystem
  • Indiana
    • Indianapolis, Indiana, United States, 46250
      • Dawes Fretzin Clinical Research Group
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • The Johns Hopkins School of Medicine
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
  • Minnesota
    • New Brighton, Minnesota, United States, 55112
      • Minnesota Clinical Study Center
  • Nebraska
    • Omaha, Nebraska, United States, 68144
      • Skin Specialists, P.C.
  • New York
    • New York, New York, United States, 10075
      • Sadick Research Group, LLC
    • Rochester, New York, United States, 14623
      • Skin Search of Rochester, Inc.
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest School of Medicine
  • Ohio
    • Mayfield Heights, Ohio, United States, 44124
      • Apex Clinical Research Center, LLC
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health & Science University
  • Pennsylvania
    • Sugarloaf, Pennsylvania, United States, 18249
      • Derm Dox Center for Dermatology
  • Texas
    • Dallas, Texas, United States, 75230
      • Dermatology Treatment and Research Center
    • Houston, Texas, United States, 77030
      • UTHealth McGovern Medical School
  • Utah
    • Salt Lake City, Utah, United States, 84108
      • University of Utah
  • Virginia
    • Lynchburg, Virginia, United States, 24501
      • The Education & Research Foundation, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subject is at least 18 years of age
2. Subject must provide written informed consent prior to any study procedures
3. Subject must have a clinical diagnosis of NF1

4. Subject has 10 clinically diagnosed Target cNFs with preferably 2 Target cNFs located on the face and 8 Target cNFs located on the anterior trunk or upper extremities. Alternatively, at least 1 Target cNF is located on the face, in which case 9 Target cNFs must be located on the anterior trunk or upper extremities. Each Target cNF must meet the following criteria:

   • Has, in the investigator's opinion, a clinically typical appearance
   • Is not within 1 cm of the orbital rim
   • Is not covered with hair that might, in the investigator's opinion, interfere with obtaining photographs or impair evaluation of the cNF
   • Has a Physician's Tumor Assessment grade ≥2
   • Is dome shaped
   • Is not pedunculated
   • Is a discrete cNF surrounded by sufficient non-affected skin that, in the investigator's opinion:
   • The dimensions can be measured
   • The perimeter can be outlined in the study photographs
   • Is not irritated (e.g., bleeding, inflamed)
   • Is not in an area subject to repeated trauma (e.g., area that is shaved, on the beltline, under a bra strap, etc.)
   • Does not have an active cutaneous infection
   • Target cNFs on the face must have the following tumor dimensions:
   • Has a length that is ≥5mm and ≤14mm
   • Has a width that is ≥5mm and ≤14mm
   • Has a height that is ≥2mm.
   • Target cNFs on the anterior trunk or upper extremities must have the following tumor dimensions:
   • Has a length that is ≥7mm and ≤14mm
   • Has a width that is ≥5mm and ≤14mm
   • Has a height that is ≥2mm.
5. Subject agrees to avoid exposure of Target cNFs to excessive sunlight and to use her/his routine sunscreen if excessive exposure cannot be avoided
6. Subject agrees NOT to use tanning beds
7. Subject is willing to forego treatment of each Target cNF, except protocol specified therapy, during the study
8. Female subjects who are women of childbearing potential must have a negative urine pregnancy test result and be willing to use a protocol approved, contraceptive method for the duration of the study
9. Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion Criteria:

1. Subject has used any of the following topical therapies within the specified period prior to Visit 1 on or in proximity to any Target cNF that, in the investigator's opinion, impairs evaluation of any the cNFs or which exposes the subject to an unacceptable risk by study participation:

   • Corticosteroids; 30 days
   • Prescription retinoids (e.g., tazarotene, tretinoin, adapalene); 30 days
   • > 5% of an alpha-hydroxy acid (e.g., glycolic acid, lactic acid); 30 days
   • Fluorouracil; 30 days
   • Imiquimod; 30 days
   • LASER, light (e.g., intense pulsed light [IPL], photo-dynamic therapy [PDT]) or other energy-based therapy; 180 days
   • MEK inhibitor or BRAF inhibitor; ever.

2. The subject has used any of the following systemic medications therapies within the specified period prior to Visit 1:

   • Retinoids (e.g., etretinate, isotretinoin); 90 days
   • MEK inhibitors; 180 days
   • BRAF inhibitors; 180 days
3. Subject has a history of hypersensitivity to any of the ingredients in the study medications
4. Subject has any known intercurrent illness or physical condition that would, in the investigator's opinion, impair evaluation of a Target cNF or which exposes the subject to an unacceptable risk by study participation
5. Subject has, in the investigator's opinion, clinically relevant history of liver disease, including viral hepatitis, current alcohol abuse, or cirrhosis
6. Subject has a history of metastatic disease, or active cancer (excluding nonmelanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or Stage 0 chronic lymphocytic lymphoma) within the previous 5 years
7. Subject has any condition (e.g., other skin conditions or diseases, metabolic dysfunction, physical examination findings, clinical laboratory findings) or situation (e.g., vacation, scheduled surgery) that would, in the investigator's opinion, impair evaluation of a Target cNF or which exposes the subject to an unacceptable risk by study participation
8. Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within the previous 30 days

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 0.5% NFX-179 gel; Topical gel applied once daily to target cNFs	Drug: NFX-179 gel; NFX-179 topical gel is the active investigational product being studied; Other Names: NFX-179 topical gel
Active Comparator: 1.5% NFX-179 gel; Topical gel applied once daily to target cNFs	Drug: NFX-179 gel; NFX-179 topical gel is the active investigational product being studied; Other Names: NFX-179 topical gel
Placebo Comparator: Vehicle gel; Topical gel applied once daily to target cNFs	Drug: Vehicle gel; NFX-179 vehicle gel is the placebo comparator for this study; Other Names: NFX-179 vehicle gel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and effectiveness of once daily NFX-179 gel treatment for 182 days measured by local tolerability assessments, safety laboratory tests, and target cNF volume reduction	Safety will be measured by routine safety laboratory tests (CBC/differential, serum chemistry, urinalysis), and local tolerability assessment where the investigator will assess erythema, edema, scabbing/crusting, vesiculation, and erosion. The subject will assess stinging, burning, and pruritus. All assessments are performed using a 4-point scale (0 none, 1 mild, 2 moderate, 3 severe). Effectiveness will be measured by the percent of treated subjects with at least a 50% reduction in cNF volume after 6 months of treatment.	182 days
Safety of once daily NFX-179 gel treatment for 182 days by adverse events and serious adverse events assessments	Safety of NFX-179 gel compared to the vehicle group will be measured by the assessment and occurrence of new and ongoing adverse events (AEs)/serious adverse events (SAEs).	182 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of subjects with at least 50% Target cNF volume reduction after 182 days	Treatment effectiveness will be measured by the percent of treated subjects with at least a 50% reduction in cNF volume after 6 months of treatment. Tumor volume will be measured by ruler measurements and two-dimensional photography. All modes of tumor volume measurement are reported in cubic millimeters.	182 days
Percent change in cNF volume over 182 days	Percent change of tumor volume will be calculated through ruler measurements and two-dimensional photography throughout the course of treatment. All modes of tumor volume measurement are reported in cubic millimeters.	182 days
Physician's Tumor Assessment of Target cNF severity over 182 days	Effect of treatment with The Physician Tumor Assessment is the investigator's assessment of the average overall severity of each Target cNF tumor at a particular time point. The Physician Tumor Assessment is a 5-point measuring tumor severity (0 clear/none, 1 almost clear, 2 mild, 3 moderate, 4 severe). This assessment is performed at Screening, Baseline/Day 1, Days 58, 183, and 211.	182 days
Subject's Self-Assessment of Target cNF severity over 182 days	The Subject Self-Assessment is the subject's assessment of the average overall severity of each Target cNF at a particular time point and is not a comparison with any other time point. The Subject Self-Assessment is a 5-point measuring tumor severity (0 clear/none, 1 almost clear, 2 mild, 3 moderate, 4 severe). This assessment is performed at Screening, Baseline/Day 1, Days 58, 183, and 211.	182 days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient Reported Outcome Measure to assess Target cNF symptoms over 182 days	This assessment is performed via the subject's assessment of their experience over the previous week with 9 items for each Target cNF (sensitivity, pain, itch, noticeability, size, appearance, care to avoid irritation, how much the cNF bothers the subject, self-consciousness). Each item is assessed by using a 5-point scale.	182 days

Collaborators and Investigators

• Sponsor: NFlection Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): September 20, 2021
• Primary Completion (Actual): October 4, 2023
• Study Completion (Actual): October 4, 2023

Study Registration Dates

• First Submitted: August 2, 2021
• First Submitted That Met QC Criteria: August 11, 2021
• First Posted (Actual): August 16, 2021

Study Record Updates

• Last Update Posted (Estimated): November 16, 2023
• Last Update Submitted That Met QC Criteria: November 15, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms; Genetic Diseases, Inborn; Neuromuscular Diseases; Neurodegenerative Diseases; Neoplasms, Nerve Tissue; Peripheral Nervous System Diseases; Nervous System Neoplasms; Heredodegenerative Disorders, Nervous System; Neoplastic Syndromes, Hereditary; Nerve Sheath Neoplasms; Neurocutaneous Syndromes; Peripheral Nervous System Neoplasms; Neurofibromatoses; Neurofibromatosis 1; Neurofibroma
• Other Study ID Numbers: NFX-179-NF1-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No